Pipeline

PROGRAM

DISEASE

DISCOVERY

PRE-CLINICAL

PHASE 1/2

PIVOTAL

AML

WU-NK-101

Head & Neck Cancer

WU-NK-101 + Cetuximab

Melanoma

WU-NK-101 (post-checkpoint inhibitor)

Solid Tumors

WU-NK-201

T-ALL

WU-CART-007

AML = Acute Myeloid Leukemia
T-ALL = T-cell Acute Lymphoblastic Leukemia

Lead Programs

WU-NK-101

Super-Charged to attack cancer

WU-CART-007

Engineered to target T-cell cancers

Next in our story
Next in our story